Corcept Therapeutics Incorporated
CORT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $208 | $194 | $157 | $182 |
| % Growth | 6.8% | 23.7% | -13.6% | – |
| Cost of Goods Sold | $5 | $3 | $2 | $3 |
| Gross Profit | $203 | $191 | $155 | $179 |
| % Margin | 97.8% | 98.2% | 98.5% | 98.4% |
| R&D Expenses | $69 | $60 | $61 | $70 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $124 | $104 | $91 | $83 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $193 | $164 | $151 | $154 |
| Operating Income | $10 | $27 | $3 | $25 |
| % Margin | 4.9% | 13.7% | 2.2% | 13.9% |
| Other Income/Exp. Net | $5 | $5 | $6 | $7 |
| Pre-Tax Income | $15 | $32 | $10 | $32 |
| Tax Expense | $4 | -$3 | -$11 | $1 |
| Net Income | $19 | $35 | $20 | $30 |
| % Margin | 9.3% | 18.1% | 12.9% | 16.7% |
| EPS | 0.19 | 0.33 | 0.19 | 0.29 |
| % Growth | -42.4% | 73.7% | -34.5% | – |
| EPS Diluted | 0.16 | 0.29 | 0.17 | 0.26 |
| Weighted Avg Shares Out | 104 | 104 | 104 | 104 |
| Weighted Avg Shares Out Dil | 119 | 120 | 120 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $5 | $6 | $7 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $16 | $27 | $4 | $26 |
| % Margin | 7.6% | 14% | 2.5% | 14.1% |